C4 Therapeutics, Inc. (CCCC) stock
CCCCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3019% above fair value
$2.77−0.12 (-4.15%)
Close on Nov 12, 2026Market cap $340.78MP/E –Yield –
C4 Therapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
C4 Therapeutics's total debt was $0 at Dec 31, 2023. For fiscal 2023 it was $0, down 100.0% from the year before.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $0 | -100.0% |
| FY2022 | Dec 31, 2022 | $11.48M | +6.6% |
| FY2021 | Dec 31, 2021 | $10.77M | +7.1% |
| FY2020 | Dec 31, 2020 | $10.05M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2023 | Dec 31, 2023 | $0 | -100.0% |
| Q3 FY2023 | Sep 30, 2023 | $0 | -100.0% |
| Q2 FY2023 | Jun 30, 2023 | $10.34M | -7.1% |
| Q1 FY2023 | Mar 31, 2023 | $10.91M | -0.3% |
| Q4 FY2022 | Dec 31, 2022 | $11.48M | +6.6% |
| Q3 FY2022 | Sep 30, 2022 | $11.30M | +6.7% |
| Q2 FY2022 | Jun 30, 2022 | $11.12M | +6.8% |
| Q1 FY2022 | Mar 31, 2022 | $10.94M | +7.0% |
| Q4 FY2021 | Dec 31, 2021 | $10.77M | +7.1% |
| Q3 FY2021 | Sep 30, 2021 | $10.59M | +7.2% |
| Q2 FY2021 | Jun 30, 2021 | $10.41M | – |
| Q1 FY2021 | Mar 31, 2021 | $10.23M | – |
| Q4 FY2020 | Dec 31, 2020 | $10.05M | – |
| Q3 FY2020 | Sep 30, 2020 | $9.88M | – |
See a number that looks wrong?